Drs Benjamin L. Schlechter and John Strickler discuss the newest testing and treatment options for HER2-amplified colorectal cancer and the findings from the MOUNTAINEER and DESTINY-CRC studies. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/988972). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study https://pubmed.ncbi.nlm.nih.gov/26610798/ Tucatinib Plus Trastuzumab for Chemotherapy-Refractory, HER2-Positive, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER): A Multicentre, Open-Label, Phase 2 Study https://pubmed.ncbi.nlm.nih.gov/37142372/ Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients With Advanced Solid Tumors https://pubmed.ncbi.nlm.nih.gov/32127466/ Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification From Aneuploidy in Diverse Advanced Cancers https://pubmed.ncbi.nlm.nih.gov/34677235/ 109P – Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis From Japan and the United States https://www.sciencedirect.com/science/article/pii/S0923753419583405 COLONTOWN https://colontown.org/colontown-on-facebook/ HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target https://pubmed.ncbi.nlm.nih.gov/35580290/ 4795 – Trastuzumab and Tucatinib for the Treatment of HER2 Amplified Metastatic Colorectal Cancer (mCRC): Initial Results From the MOUNTAINEER Trial https://oncologypro.esmo.org/meeting-resources/esmo-2019-congress/Trastuzumab-and-tucatinib-for-the-treatment-of-HER2-amplified-metastatic-colorectal-cancer-mCRC-Initial-results-from-the-MOUNTAINEER-trial Seattle Genetics to Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program to Its Oncology Pipeline https://www.businesswire.com/news/home/20180131005494/en/Seattle-Genetics-to-Acquire-Cascadian-Therapeutics-Adding-Late-Stage-Breast-Cancer-Program-to-Its-Oncology-Pipeline Trastuzumab Deruxtecan (T-DXd) Versus Treatment of Physician's Choice (TPC) in Patients (Pts) With HER2-Low Unresectable and/or Metastatic Breast Cancer (mBC): Results of DESTINY-Breast04, a Randomized, Phase 3 Study https://meetings.asco.org/abstracts-presentations/209021 DESTINY-Breast04 Establishes Trastuzumab Deruxtecan as a New Standard of Care for HER2-Low Metastatic Breast Cancer https://dailynews.ascopubs.org/do/destiny-breast04-establishes-trastuzumab-deruxtecan-new-standard-care-her2-low Final Results of DESTINY-CRC01 Investigating Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer https://pubmed.ncbi.nlm.nih.gov/37286557/ Trastuzumab Deruxtecan (T-DXd) in Patients (Pts) With HER2-Overexpressing/Amplified (HER2+) Metastatic Colorectal Cancer (mCRC): Primary Results From the Multicenter, Randomized, Phase 2 DESTINY-CRC02 Study https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.3501?af=R Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments https://pubmed.ncbi.nlm.nih.gov/35837349/ KRASG12C Inhibition With Sotorasib in Advanced Solid Tumors https://pubmed.ncbi.nlm.nih.gov/32955176/ 315O – Sotorasib in Combination With Panitumumab in Refractory KRASG12C-Mutated Colorectal Cancer: Safety and Efficacy for Phase Ib Full Expansion Cohort https://oncologypro.esmo.org/meeting-resources/esmo-congress/sotorasib-in-combination-with-panitumumab-in-refractory-kras-g12c-mutated-colorectal-cancer-safety-and-efficacy-for-phase-ib-full-expansion-cohort

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related